Pharmaceutical formulation comprising a phosphodiesterase inhibitor.

Abstract

The invention relates to a pharmaceutical formulation to be administered by pressurized metered dose inhalers (pMDIs), comprising: (a) the (-) enantiomer of 3-cyclopropylmethoxy-4methanesulfonylaminobenzoic acid 1 -(3 -cyclopropylmethoxy-4difluoromethoxyphenyl)-2-(3 , 5 -dichloro- 1 oxypyrid in-4-yl)ethyl ester; a propellant; a co-solvent; and a surfactant selected from the group consisting of a PEG surfactant, a PVP surfactant, and a mixture thereof. may be used for the treatment of inflammatory or obstructive airway diseases.